Genomatix Gets $500K in Series B Private Equity Round

May 18, 2005

NEW YORK, May 18 (GenomeWeb News) - Genomatix, a Roanoke, Va.-based gene expression and proteomics tools company, today announced that it has closed a Series B round of financing led by a $500,000 investment from NewVa Capital Partners, a venture capital fund managed by Third Security.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Synthetic Genomics Sued for Gender Discrimination

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Football Team's DNA Day Postponed

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

This Week in Cell

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Main menu